[¹⁷⁷Lu]镥标记的前列腺特异性膜抗原（PSMA）配体诱导转移性前列腺癌患者缓解 - Suppr

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

作者信息

Kratochwil Clemens, Giesel Frederik L, Eder Matthias, Afshar-Oromieh Ali, Benešová Martina, Mier Walter, Kopka Klaus, Haberkorn Uwe

机构信息

Department for Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany,

出版信息

Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8. doi: 10.1007/s00259-014-2978-1. Epub 2015 Jan 9.

DOI:10.1007/s00259-014-2978-1

PMID:25573634

Abstract

摘要

相似文献

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):987-8. doi: 10.1007/s00259-014-2978-1. Epub 2015 Jan 9.

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29.

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.

Nucl Med Commun. 2017 Jan;38(1):91-98. doi: 10.1097/MNM.0000000000000606.

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.

Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.

Clin Nucl Med. 2016 Feb;41(2):159-60. doi: 10.1097/RLU.0000000000001058.

A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1611-1613. doi: 10.1007/s00259-017-3767-4. Epub 2017 Jul 4.

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):193-194. doi: 10.1007/s00259-015-3235-y. Epub 2015 Oct 27.

Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.

Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31.

Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.

Expert Rev Mol Diagn. 2016 Nov;16(11):1177-1188. doi: 10.1080/14737159.2016.1243057. Epub 2016 Oct 14.

Lutetium PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227.

引用本文的文献

Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.

Curr Oncol Rep. 2025 Aug 27. doi: 10.1007/s11912-025-01686-y.

Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.

Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.

Exploring the Therapeutic Potential of Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases.

Int J Mol Sci. 2025 Jun 21;26(13):5970. doi: 10.3390/ijms26135970.

Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure.

Cancers (Basel). 2025 May 21;17(10):1723. doi: 10.3390/cancers17101723.

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials.

Discov Oncol. 2024 Dec 18;15(1):791. doi: 10.1007/s12672-024-01680-z.

Novel astatine (At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):469-481. doi: 10.1007/s00259-024-06945-x. Epub 2024 Oct 12.

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer.

Clin Med Insights Oncol. 2024 Sep 19;18:11795549241277181. doi: 10.1177/11795549241277181. eCollection 2024.

Design of Ac-PSMA for targeted alpha therapy in prostate cancer.

Ann Transl Med. 2024 Aug 1;12(4):67. doi: 10.21037/atm-23-1842. Epub 2024 Mar 6.

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.

Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective.

Cancers (Basel). 2024 Apr 25;16(9):1643. doi: 10.3390/cancers16091643.

本文引用的文献

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Urol Oncol. 1995 Jan-Feb;1(1):18-28. doi: 10.1016/1078-1439(95)00002-y.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Cancer Res. 1998 Sep 15;58(18):4055-60.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献